证券代码：301520 证券简称：万邦医药 公告编号：2025-031 安徽万邦医药科技股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日 召开第二届董事会第十五次会议和第二届监事会第九次会议，审议通过了《关于 使用部分超募资金回购公司部分股份方案的议案》，同意公司使用超募资金以集 中竞价交易方式回购公司部分社会公众股股份并用于股权激励计划或员工持股 计划，用于回购股份的总金额为 1,500 万元-3,000 万元，回购价格不超过 60.62 元/股（含），具体回购股份的数量及金额以回购期满时实际回购的股份数量及金 额为准。本次回购的实施期限为董事会审议通过回购方案之日起 12 个月内。具 体内容详见公司于巨潮资讯网（www.cninfo.com.cn）上披露的《关于使用部分 超募资金回购公司部分股份方案的公告》（公告编号：2024-040）和《回购报告 书》（公告编号：2024-042）。 鉴于公司已实施完成 2024 年前三季度权益分派方 ...

安徽万邦医药科技股份有限公司的主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包 服务。公司的主要产品是临床试验现场管理（SMO）、生物样本分析（BA）、数据管理与统计分析 （DM/ST）、处方工艺研究、质量研究、稳定性研究。 序号股票简称PE(TTM)PE(静)市净率总市值(元)29万邦医药41.3132.701.8727.97亿行业平均 40.3546.493.46158.30亿行业中值47.2152.292.7259.39亿1润达医疗-285.64189.022.47104.49亿2何氏眼 科-142.30-123.831.7733.93亿3*ST生物-118.20-114.919.7122.80亿4诚达药业-74.55-127.721.6835.89亿5普 瑞眼科-66.51-59.752.8560.87亿6皓宸医疗-52.44-63.076.2223.77亿7创新医疗-50.98-56.933.0353.48亿8国际 医学-45.16-45.423.23115.42亿9百诚医药-36.42-88.911.8446.89亿10金域医学-35.05-35.891.99136.85亿11睿 智医 ...

Market Overview - As of 13:59 today, the Shanghai Composite Index is at 3372.33 points, with a slight decline of -0.23% [1] - The total trading volume of A-shares today is 838.849 billion yuan [1] Stocks Breaking Annual Line - A total of 68 A-shares have surpassed their annual line today, with notable stocks including: - Puris (乖离率 6.48%) - Aisen Co., Ltd. (乖离率 5.81%) - Fosa Technology (乖离率 4.02%) [1] Stocks with Significant Deviation - The stocks with the largest deviation from the annual line include: - Puris: Today's price increased by 7.19% to 30.70 yuan - Aisen Co., Ltd.: Today's price increased by 7.47% to 42.00 yuan - Fosa Technology: Today's price increased by 4.30% to 32.71 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance and their respective deviations include: - Yao Stone Technology: 3.77% increase, 3.51% deviation - Fuling Power: 6.24% increase, 3.42% deviation - Yingjie Electric: 5.37% increase, 3.38% deviation [1] Summary of Stocks with Minor Deviations - Stocks with minor deviations from the annual line include: - Huayang Intelligent: 4.58% increase, 2.48% deviation - Boying Special Welding: 2.32% increase, 2.06% deviation - Stone Technology: 2.02% increase, 1.96% deviation [1]

板块涨幅居前的十大牛股分别是：阳光诺和（5.1%）、毕得医药（1.52%）、昭衍新药（0.88%）、药 康生物（0.85%）、诺泰生物（0.79%）、泓博医药（0.77%）、百诚医药（0.61%）、联化科技 （0.47%）、昊帆生物（0.45%）、泰格医药（0.4%）、美迪西（0.3%）、金凯生科（0.06%）、皓元医 药（0.05%）、迦南科技（0.0%）、睿智医药（0.0%）、太龙药业（-0.18%）、成都先导（-0.2%）、 义翘神州（-0.23%）、百花医药（-0.28%）、凯莱英（-0.33%） 本文源自：金融界 序代码股票名称现价涨跌幅主力资金净额主力资金净占比1300630普利退0.82-8.89-415.18 万-16.232301520万邦医药38.8-2.56-119.21万-1.503300759康龙化成22.41-2.52-2033.75万-4.674603739蔚 蓝生物13.6-1.73-655.01万-4.535603229奥翔药业8.13-1.69-488.23万-7.946000739普洛药业13.81- 1.642593.46万12.907688238和元生物5.71-1. ...

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

Group 1: Financial Performance - The company's net profit decreased by 20.87% in 2024 compared to 2023, primarily due to intense market competition and reduced gross margins [3][4] - Revenue and profit decline attributed to traditional business challenges, prompting a strategic shift towards "medical CRO" [3][4] Group 2: Strategic Direction - The company aims to transition from "pharmaceutical CRO" to "healthcare CRO," focusing on international markets while solidifying its domestic position [3][4] - Key strategic points include exploring international markets, enhancing digital innovation, and developing a health industry ecosystem centered on anti-aging and functional health products [3][4][5] Group 3: Research and Development - R&D investment increased by 75.78%, indicating a new strategic focus on research [4][5] - Ongoing projects like 22FN24 and 22BL5 are expected to generate new revenue upon obtaining drug registration certificates [5] Group 4: Competitive Advantage - The company’s competitiveness in clinical research services is supported by comprehensive trial coverage, high project experience, advanced equipment, and a skilled team [4] - The company is actively exploring the health industry ecosystem and plans to invest or acquire related enterprises to enhance its industry chain [5] Group 5: International Expansion - The company is researching opportunities in international markets, particularly in Europe, North America, and Southeast Asia, but has not yet established partnerships with foreign clients [5]

暗盘资金正涌入这些股票，点击速看>>> 创新药板块拉升，哈三联（002900）涨停，万邦医药（301520）涨超10%，九芝堂（000989）、科伦药 业（002422）、凯莱英（002821）纷纷拉升。 ...

Group 1 - The company held its 12th meeting of the second Supervisory Board on May 13, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal for the initial grant of restricted stock under the 2025 incentive plan, confirming that the conditions for granting and the eligibility of the incentive objects were met [1][2] - A total of 509,375 restricted shares will be granted to 88 incentive objects at a price of 19.75 yuan per share, with the grant date set as May 13, 2025 [2]

关于安徽万邦医药科技股份有限公司 2024 年年度股东大会的 法律意见书 安徽承义律师事务所 ANHUI CHENGYI LAW FIRM 地址：合肥市政务区怀宁路 200 号栢悦中心大厦五楼、八楼 邮编：230071 电话：0551-65609815 传真：0551-65608051 安徽承义律师事务所 法律意见书 安徽承义律师事务所 安徽承义律师事务所 关于安徽万邦医药科技股份有限公司 2024年年度股东大会的法律意见书 (2025)承义法字第00079号 致：安徽万邦医药科技股份有限公司 安徽承义律师事务所（以下称"本所"）接受安徽万邦医药科技股份有限公司（以 下称"公司"）的委托，指派本律师以现场结合视频方式出席并对公司 2024 年年度 股东大会（以下称"本次股东大会"）进行见证。 _________________________________________________________________________________ 安徽承义律师事务所 法律意见书 1、现场会议时间：2025 年 5 月 13 日（星期二）下午 14:00； 2、网络投票时间：2025 年 5 月 13 日 ...

证券代码：301520 证券简称：万邦医药 公告编号：2025-027 安徽万邦医药科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、 本次股东大会不存在否决议案的情形。 2、召开地点：安徽省合肥市高新区火龙地路299号213会议室。 3、召开方式：现场表决与网络投票相结合的方式 4、召集人：公司董事会 5、主持人：董事长、总经理陶春蕾女士 6、本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东大 会规则》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门 规章、规范性文件和《安徽万邦医药科技股份有限公司章程》的有关规定。 7、会议出席情况 2、 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1） 现场会议召开时间：2025年5月13日（星期二）14：00； （2） 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体 时间为：2025年5月13日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证 ...